Longeveron Inc
NASDAQ:LGVN
Longeveron Inc
Revenue
Longeveron Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Longeveron Inc
NASDAQ:LGVN
|
Revenue
$709k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
See Also
What is Longeveron Inc's Revenue?
Revenue
709k
USD
Based on the financial report for Dec 31, 2023, Longeveron Inc's Revenue amounts to 709k USD.
What is Longeveron Inc's Revenue growth rate?
Revenue CAGR 5Y
-20%
Over the last year, the Revenue growth was -42%. The average annual Revenue growth rates for Longeveron Inc have been -50% over the past three years , -20% over the past five years .